VANI

#3831
Vivani Medical, Inc. - Common Stock
1.3 7 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
1.35
1.38
Intervallo Annuale
0.92
1.92
Variazione giornaliera
-1.44%
Variazione Mensile
0.00%
Variazione di 6 mesi
+13.22%
Variazione Annuale
+20.18%
Chiusura Precedente
1.3 9
Open
1.3 7
Minimo
1.3 5
Massimo
1.3 8
Volume
32
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, 17 Aug 2026
Vivani Medical, Inc. current report, 17 August 2026
8-K
Current report, Q3 FY2026
Vivani Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Vivani Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Vivani Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Vivani Medical, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Vivani Medical, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Vivani Medical, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vivani Medical, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vivani Medical, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Vivani Medical, Inc. quarterly report, Q1 FY2026
10-Q

Vivani Medical, Inc. current report, Q2 FY2025

Full document

Vivani Medical, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Vivani Medical, Inc. (Nasdaq: VANI) on June 11, 2025. The report discloses significant changes in executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor, effective June 15, 2025.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on personnel changes and compensatory arrangements.

Material Changes

  • Departure of CFO: Brigid Makes resigned as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer. Her resignation is effective June 15, 2025, and was not based on any disagreement with the Company regarding operations, policies, or practices.
  • Appointment of New CFO: Anthony Baldor was appointed to succeed Ms. Makes as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective June 15, 2025.
  • Compensation Package: Mr. Baldor's compensation includes:
    • Base salary of $450,000 per year.
    • Eligibility for a cash bonus program with goals to be determined by the Compensation Committee.
    • Option award to purchase 600,000 shares of common stock at fair market value on the grant date.
    • Vesting schedule: 25% on the first anniversary of the Effective Date, with the remainder vesting ratably over the subsequent three years.

Outlook, Risks, and Management Commentary

The filing states that Mr. Baldor brings experience from Diakonos Oncology Corp., 4D Molecular Therapeutics, Inc., and Jefferies Group, LLC. The Company issued a press release on June 11, 2025, regarding these changes. No specific financial guidance, risks, or contingencies were disclosed in this report.

Key Facts for Investor Verification

  • Verify the transition timeline for the CFO role effective June 15, 2025.
  • Review the full text of the Offer Letter agreement, which is expected to be filed as an exhibit to the Form 10-Q for the quarter ended June 30, 2025.
  • Confirm the vesting terms and exercise price of the 600,000 stock options granted to the new CFO.
  • Monitor future filings for any impact of this leadership change on the Company's financial reporting or strategic direction.

Notizie